Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Convertible Debt Current Assets Current Deferred Revenue Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Standard Biotools (LAB) Long-Term Deferred Tax (2024 - 2026)

Standard Biotools has reported Long-Term Deferred Tax over the past 2 years, most recently at $51.8 million for Q4 2025.

Quarterly Long-Term Deferred Tax fell 83.72% to $51.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $51.8 million through Dec 2025, down 83.72% year-over-year, with the annual reading at $51.8 million for FY2025, 83.72% down from the prior year.
Long-Term Deferred Tax was $51.8 million for Q4 2025 at Standard Biotools, down from $318.0 million in the prior quarter.
Over five years, Long-Term Deferred Tax peaked at $318.0 million in Q4 2024 and troughed at $51.8 million in Q4 2025.